Botulinum toxin type A treatment of four cases of Wilson disease with lower limb dystonia: A prospective study.

Abstract

Botulinum toxin type A (BoNT-A) has been recommended in various neurological disorders as a useful tool for alleviating dystonia. In Wilson disease (WD) patients with dystonia, BoNT-A injection can be used as a treatment modality when conventional treatment is ineffective for alleviating symptoms. The purpose of this study was to thoroughly evaluate the efficacy of BoNT-A injection in treating WD complicated by lower extremity dystonia. The efficacy of these injections was assessed by clinical scales, surface electromyography (EMG), and gait analysis. A comparative analysis of all gait parameters, EMG parameters, and clinical scales revealed a significant increase in velocity, decrease in integrated EMG (iEMG), and improvement in modified Ashworth scale (MAS), Burke Fahn Marsden (BFM), and activities of daily living (ADL) scores (all P < 0.05). Overall, our findings indicated that BoNT-A injection led to marked relief of symptoms in patients with WD with lower extremity dystonia.

• Authors: Zeyu Cao, Rao Rao, Tong Wu, Shangzhi Chen, Saiwei Xing, Yongsheng Han
• Journal: Toxicon : official journal of the International Society on Toxinology (Toxicon) Vol. 221 Pg. 106959 (Jan 01 2023) ISSN: 1879-3150 [Electronic] England
• PMID: 36343759 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Botulinum Toxins, Type A
• Neuromuscular Agents

Topics

• Humans
• Botulinum Toxins, Type A (therapeutic use)
• Dystonia (drug therapy)
• Prospective Studies
• Hepatolenticular Degeneration (drug therapy)
• Activities of Daily Living
• Dystonic Disorders (drug therapy)
• Treatment Outcome
• Neuromuscular Agents (therapeutic use)